用户报告的长效注射PrEP与Cabotegravir的结果:来自米兰的现实世界经验
Angelo Roberto Raccagni1, Flavia Passini1, Riccardo Lolatto2
1Vita-Salute San Raffaele University, Milan, Italy.
HIV medicine
|December 1, 2025
概括
长效注射卡博特格拉维尔 (CAB-LA) PrEP在欧洲实际使用中具有高度可接受性和耐受性. 与每日口服PrEP相比,这种艾滋病毒预防方法提高了坚持,方便和感知到的保护.
科学领域:
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
- 药理学 药理学是指药理学的学科.
背景情况:
- 艾滋病毒的口服预暴露预防 (PrEP) 是有效的,但面临着坚持和副作用的挑战.
- 长效注射卡博特格拉维尔 (CAB-LA) 是一种谨慎而方便的替代口服PrEP.
- 关于欧洲CAB-LA使用的现实数据有限.
研究的目的:
- 评估开始使用 CAB-LA PrEP 的人员用户报告的结果.
- 评估与CAB-LA相关的满意度,坚持,感知到的保护,生活质量和不良事件.
- 了解CAB-LA在欧洲环境中的实际有效性和用户体验.
主要方法:
- 在2024年11月至2025年7月期间接受CAB-LA的参与者的前性队列研究.
- 通过每次注射访问的自我报告调查收集的数据.
- 结果包括满意度,坚持,感知到的保护,生活质量和不良事件 (例如,注射部位反应).
主要成果:
- 包括82名cis-MSM参与者 (平均年龄为41.4岁).
- 报告说,对CAB-LA的满意度很高,在第四次注射时有90.9%的积极意见.
- 与口服PrEP相比,改善了坚持 (75.3%),方便 (> 94%) 和感知到的保护 (84.4%).
- 副作用通常是轻微的,有不常见的全身事件和最小的注射部位反应.
结论:
- 在现实世界的欧洲队列中,CAB-LA PrEP具有高度可接受性和耐受性.
- CAB-LA证明了感知依从性,方便性和艾滋病毒保护的改善.
- 长效注射卡博特格拉维尔是一种有希望的,以用户为中心的艾滋病毒预防策略,可以克服口服PrEP的局限性.
相关概念视频
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


